Drug Trial Radar · NCT07712484
A Phase II Randomized Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis Treated With Olorofim Plus Baseline Standard of Care or Placebo Plus Baseline Standard of Care
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Jun 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- F2G LtdIndustry
- Sponsor type
- Industry
- Collaborators
- IQVIA RDS Inc.
- First posted
- Jul 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test measurement tools (questionnaire about symptoms and a questionnaire about quality of life) to assess usability in the assessment of treatment effectiveness for people with disseminated coccidioidomycosis (DCM).
Conditions
- Coccidioidomycosis
- Disseminated Fungal Infection
- Coccidioides Infection
- Coccidioides Immitis Infection
- Coccidioides Posadasii Infection
- Coccidioidomycosis Infection
- San Joaquin Valley Fever
- Valley Fever
Interventions
OlorofimDrug
Arm A: Oral olorofim loading dose: 5 tablets (150 mg) to be taken twice daily at a 12-hour (± 1 hour) interval on Day 1 followed by a maintenance dose of 3 tablets (90 mg) to be taken twice daily at 12-hour (± 1 hour) intervals from Day 2 until Day 168 (± 7 days)
PlaceboDrug
Arm B: Oral olorofim-matched placebo loading dose: 5 tablets (150 mg) to be taken twice daily at a 12-hour (± 1 hour) interval on Day 1 followed by a maintenance dose of 3 tablets (90 mg) to be taken twice daily at 12-hour (± 1 hour) intervals from Day 2 until Day 168 (± 7 days)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Valley Fever - Patient Reported Outcomes (VF-PRO) Mobility domain scoreTime frame: Day 168
- Change from baseline in Valley Fever - Patient Reported Outcomes (VF-PRO) Daily Function domain scoreTime frame: Day 168
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.